Daniel N. Swisher, Jr. Sells 2,200 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $59.46, for a total value of $130,812.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Monday, November 11th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $59.88, for a total value of $131,736.00.

Corcept Therapeutics Stock Performance

CORT opened at $55.40 on Friday. Corcept Therapeutics Incorporated has a twelve month low of $20.84 and a twelve month high of $62.22. The stock has a market cap of $5.80 billion, a PE ratio of 43.97 and a beta of 0.51. The business’s 50 day moving average is $53.06 and its 200-day moving average is $41.15. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. During the same quarter in the previous year, the firm posted $0.28 EPS. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. On average, analysts predict that Corcept Therapeutics Incorporated will post 1.35 earnings per share for the current year.

Analyst Ratings Changes

CORT has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Piper Sandler raised their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, September 18th. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Finally, Truist Financial raised their price target on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday, September 30th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $65.25.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors have recently bought and sold shares of CORT. Capital Performance Advisors LLP bought a new stake in shares of Corcept Therapeutics during the 3rd quarter worth about $25,000. Kathleen S. Wright Associates Inc. acquired a new position in shares of Corcept Therapeutics during the third quarter valued at approximately $36,000. GAMMA Investing LLC raised its holdings in Corcept Therapeutics by 85.4% during the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 1,147 shares in the last quarter. KBC Group NV lifted its position in Corcept Therapeutics by 21.3% in the third quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 496 shares during the period. Finally, Blue Trust Inc. boosted its stake in Corcept Therapeutics by 125.4% during the 2nd quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,962 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.